Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion announces excellent financial results for 2016

Jean-Paul Clozel, CEO: With Johnson & Johnson’s proposed acquisition of Actelion and the spin-out of a new R&D company, we have created unprecedented value for all of our stakeholders.

Jean-Paul Clozel, CEO: With Johnson & Johnson’s proposed acquisition of Actelion and the spin-out of a new R&D company, we have created unprecedented value for all of our stakeholders.

Global Actelion

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 11:04:05 CET 24/02/2017
CHF 269,00Up Down image
+0,20 (+0,07%)